Preclinical data supports potential of
P-ckit-ALLO1 as a less toxic preconditioning agent for
hematopoietic stem cell (HSC) transplants
P-ckit-ALLO1 eliminates >95% of
hematopoietic stem and progenitor cells (HSPCs) and prolongs
survival in mouse models of acute myeloid leukemia (AML)
SAN
DIEGO, May 17, 2022 /PRNewswire/ -- Poseida
Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage
biopharmaceutical company utilizing proprietary genetic engineering
platform technologies to create cell and gene therapeutics with the
capacity to cure, today will present preclinical data at the
American Society of Gene and Cell Therapy (ASGCT) 2022 Annual
Meeting highlighting the use of anti-c-kit CAR-T cells as a
preconditioning agent to enable hematopoietic stem cell (HSC)
transplants. The ASGCT Annual Meeting is being held in Washington, D.C. and virtually May 16-19, 2022.
"We are pleased to present preclinical data from our anti-c-kit
CAR-T program demonstrating the broad capabilities of our platform
technologies to potentially improve patient outcomes," said
Devon Shedlock, Ph.D., Chief
Scientific Officer, Cell Therapies at Poseida Therapeutics.
"P-ckit-ALLO1 is an allogeneic or 'off-the-shelf' adoptive cell
therapy comprised of early memory T cells expressing key bone
marrow homing markers that enable it to effectively eliminate
hematopoietic stem cells (HSC) and robustly inhibit growth of acute
myeloid leukemia (AML) cells in animal models. The data presented
today show that P-ckit-ALLO1 could be an ideal treatment as both a
safer HSC transplantation approach as well as an anti-tumor
therapy."
Presentation details:
Poster Presentation: Anti-c-kit CAR-T Cells
Enable HSC Engraftment in a Humanized Model of Stem Cell Transplant
Conditioning
Session Title: Cell Therapies
II
Session Date/Time: Tuesday, May 17, 2022, 5:30 –
6:30 PM ET
Poster Board Number: Tu-239
Location: Walter E. Washington Convention Center, Hall
D
Abstract Number: 734
P-ckit-ALLO1 leverages the Company's proprietary
piggyBac® Gene Delivery System, Cas-CLOVER™
Site-specific Gene Editing System, and a proprietary "Booster
Molecule" to develop fully allogeneic CAR-T cells targeting human
c-kit, which is highly expressed on HSCs as well as on myeloid
malignancies such as AML, meaning the treatment can be used for
either HSC transplant conditioning or as a treatment for AML. In
addition to the CAR gene, the piggyBac transposon includes a
selection marker for generation of a pure CAR+ product and a
proprietary fast-acting safety switch enabling rapid clearance of
the reactive CAR-T cells prior to donor HSC transplant.
Data demonstrated that P-ckit-ALLO1 was able to eliminate 95% of
HSCs in bone marrow within four days, which was sufficient to
enable HSC transplant in a humanized mouse model with reduced acute
myelotoxicity compared to busulfan. In addition, data demonstrated
that P-ckit-ALLO1 was able to significantly inhibit growth of AML
cells in animal models and significantly prolong survival. These
encouraging data support the potential of anti-c-kit CAR-T cells
for use as an alternative and less toxic conditioning regimen to
facilitate HSC transplantation as well as a potential anti-tumor
therapy.
About Poseida Therapeutics,
Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical
company dedicated to utilizing our proprietary genetic engineering
platform technologies to create next generation cell and gene
therapeutics with the capacity to cure. We have discovered and are
developing a broad portfolio of product candidates in a variety of
indications based on our core proprietary platforms, including our
non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-specific
Gene Editing System and nanoparticle- and AAV-based gene delivery
technologies. Our core platform technologies have utility, either
alone or in combination, across many cell and gene therapeutic
modalities and enable us to engineer our portfolio of product
candidates that are designed to overcome the primary limitations of
current generation cell and gene therapeutics. To learn more, visit
www.poseida.com and connect with us on Twitter and LinkedIn.
Forward-Looking
Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements include statements
regarding, among other things, the potential benefits of Poseida's
technology platforms and product candidates, Poseida's plans and
strategy with respect to developing its technologies and product
candidates, and anticipated timelines and milestones with respect
to Poseida's development programs and manufacturing activities.
Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or
implied by such forward-looking statements. These forward-looking
statements are based upon Poseida's current expectations and
involve assumptions that may never materialize or may prove to be
incorrect. Actual results could differ materially from those
anticipated in such forward-looking statements as a result of
various risks and uncertainties, which include, without limitation,
risks and uncertainties associated with development and regulatory
approval of novel product candidates in the biopharmaceutical
industry and the other risks described in Poseida's filings with
the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Poseida undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were made,
except as required by law.
###
View original content to download
multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-presents-encouraging-preclinical-data-highlighting-p-ckit-allo1-at-the-asgct-2022-annual-meeting-301548549.html
SOURCE Poseida Therapeutics, Inc.